Cleveland Clinic

This Week in PLOS

In PLOS this week: cancer predisposition among Cowden/Cowden-like and Bannayan-Riley-Ruvalcaba syndrome patients, and more.

At the Cleveland Clinic Medical Innovation Summit, experts discussed the promise and challenges of genomic and health data, and strategies for taming it.

Two studies led by Cleveland Clinic researchers found that a variant in a gene involved in androgen synthesis can help predict response to different prostate cancer therapies.

Tempus will provide molecular sequencing and data analysis for patients with metastatic or incurable cancer enrolled in a Cleveland Clinic study.

The test uses the company's SIA platform, a protein biomarker technology that measures different protein isoform populations to assess patient disease states.

Through studies of individuals with an inherited cancer predisposition syndrome, researchers identified germline mutations contributing to sporadic thyroid cancer as well.

The Precision Medicine Exchange Consortium will bring together cancer research institutions to share information and promote genomic profiling in treatment.

The partners will collaborate broadly but start with whole-genome sequencing to find new genes and molecular pathways associated with heart disease.

The partners will use Watson's cognitive capabilities to reduce to minutes from weeks the translation of DNA information to create a genetic profile of a patient.

Besides optimizing open-source code, the company has forged focused partnerships with multiple bioinformatics firms including Edico Genome and Curoverse. 

Pages

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.